Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 27;11(5):276.
doi: 10.3390/metabo11050276.

Preliminary Results of CitraVes™ Effects on Low Density Lipoprotein Cholesterol and Waist Circumference in Healthy Subjects after 12 Weeks: A Pilot Open-Label Study

Affiliations

Preliminary Results of CitraVes™ Effects on Low Density Lipoprotein Cholesterol and Waist Circumference in Healthy Subjects after 12 Weeks: A Pilot Open-Label Study

Stefania Raimondo et al. Metabolites. .

Abstract

Appropriate monitoring and control of modifiable risk factors, such as the level of low-density lipoprotein cholesterol (LDL-C) and other types of dyslipidemia, have an important role in the prevention of cardiovascular diseases (CVD). Recently, various nutraceuticals with lipid-lowering effects have gained attention. In addition to the plant-derived bioactive compounds, recent studies suggested that plant cells are able to release small lipoproteic structures named extracellular vesicles (EVs). The interaction between EVs and mammalian cells could lead to beneficial effects through anti-inflammatory and antioxidant activities. The present study aimed to assess the safety of the new patented plant-based product citraVes™, containing extracellular vesicles (EVs) from Citrus limon (L.) Osbeck juice, and to investigate its ability to modulate different CV risk factors in healthy subjects. A cohort of 20 healthy volunteers was recruited in a prospective open-label study. All participants received the supplement in a spray-dried formulation at a stable dose of 1000 mg/day for 3 months. Anthropometric and hematobiochemical parameters were analyzed at the baseline and after the follow-up period of 1 and 3 months. We observed that the supplement has an effect on two key factors of cardiometabolic risk in healthy subjects. A significant change in waist circumference was found in women after 4 (85.4 [79.9, 91.0] cm, p < 0.005) and 12 (85.0 [80.0, 90.0] cm, p < 0.0005) weeks, when compared to the baseline value (87.6 [81.7, 93.6] cm). No difference was found in men (baseline: 100.3 [95.4, 105.2] cm; 4 weeks: 102.0 [95.7, 108.3] cm; 12 weeks: 100.0 [95.3, 104.7] cm). The level of LDL-C was significantly lower at 12 weeks versus 4 weeks (p = 0.0064). Our study evaluated, for the first time, the effects of a natural product containing plant-derived EVs on modifiable risk factors in healthy volunteers. The results support the use of EV extracts to manage cardiometabolic risk factors successfully.

Keywords: Citrus limon (L.) Osbeck; LDL cholesterol; cardiovascular risk; flavonoids; nutraceuticals.

PubMed Disclaimer

Conflict of interest statement

The authors Raimondo, Conigliaro, Corleone and Alessandro are co-founders of the Innovative StartUp and SpinOff of the University of Palermo, Navhetec s.r.l. Some of the authors are inventors of the patents: IT patent N. 102019000005090 (issued on 19 February 2021) and PCT n. PCT/IB2020/053183. CitraVesTM is a property of Navhetec s.r.l. Prof. Rizzo is a full-time Professor of Internal Medicine at the University of Palermo, Italy, and currently Medical Director, Novo Nordisk Eastern Europe; he has conducted lectures, received honoraria and research support, and participated in conferences, advisory boards, and clinical trials sponsored by many pharmaceutical companies including Amgen, Astra Zeneca, Boehringer Igelheim, Kowa, Eli Lilly, Meda, Mylan, Merck Sharp & Dohme, Novo Nordisk, Novartis, Roche Diagnostics, Sanofi and Servier. None of the above had any role in this article, which has been written independently, without any financial or professional help, and reflects only the opinion of the authors, without any role of the industry.

Figures

Figure 1
Figure 1
(A) The chromatographic analyses of the compounds identified in the supplement. (B) Quantitative data of the compounds quantified in the supplement. (C) DLS analysis of vesicles contained in the supplement.
Figure 2
Figure 2
Flowchart of the study enrollment process. Due to the slightly, although not clinically significant, increase in values of waist circumference, triglycerides levels, and blood pressure during the follow-up period, one screened subject was excluded from analyses.

References

    1. Hartley A., Marshall D.C., Salciccioli J.D., Sikkel M.B., Maruthappu M., Shalhoub J. Trends in mortality from ischemic heart disease and cerebrovascular disease in europe: 1980 to 2009. Circulation. 2016;133:1916–1926. doi: 10.1161/CIRCULATIONAHA.115.018931. - DOI - PubMed
    1. Townsend N., Wilson L., Bhatnagar P., Wickramasinghe K., Rayner M., Nichols M. Cardiovascular disease in Europe 2016: An epidemiological update. Eur. Heart J. 2016;37:3182–3183. doi: 10.1093/eurheartj/ehw334. - DOI - PubMed
    1. Imamura F., Micha R., Khatibzadeh S., Fahimi S., Shi P., Powles J., Mozaffarian D. Dietary quality among men and women in 187 countries in 1990 and 2010: A systematic assessment. Lancet Glob. Health. 2015;3:e132–e142. doi: 10.1016/S2214-109X(14)70381-X. - DOI - PMC - PubMed
    1. Dolzhenko M.M., Barnett O.Y., Grassos C., Dragomiretska N.V., Goloborodko B.I., Ilashchuk T.O., Zuiev K.O., Karpenko O.V., Kolesnikova O.V., Kolesnyk T.V., et al. Management of dyslipidemia in individuals with low-to-moderate cardiovascular risk: Role of nutraceuticals. Adv. Ther. 2020;37:4549–4567. doi: 10.1007/s12325-020-01490-z. - DOI - PubMed
    1. Aronson J.K. Defining “nutraceuticals”: Neither nutritious nor pharmaceutical. Br. J. Clin. Pharmacol. 2017;83:8–19. doi: 10.1111/bcp.12935. - DOI - PMC - PubMed

LinkOut - more resources